{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T19:13:28Z","timestamp":1787944408016,"version":"build-2784847793"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01265-1","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T16:06:18Z","timestamp":1753200378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Outcomes of Conversion Surgery vs Conventional Systemic Therapy in Stage IV Gastric Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9533-801X","authenticated-orcid":false,"given":"Kai Siang","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5139-561X","authenticated-orcid":false,"given":"Liyang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1978-0636","authenticated-orcid":false,"given":"Aung Myint","family":"Oo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"1265_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1265_CR2","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/jjco\/hyy077","volume":"48","author":"C Hamashima","year":"2018","unstructured":"Hamashima C. Update version of the Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol. 2018;48:673\u201383. https:\/\/doi.org\/10.1093\/jjco\/hyy077.","journal-title":"Jpn J Clin Oncol"},{"key":"1265_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5230\/jgc.2023.23.e11","volume":"23","author":"T-H Kim","year":"2023","unstructured":"Kim T-H, Kim I-H, Kang SJ, Choi M, Kim B-H, Eom BW, et al. Korean practice guidelines for gastric cancer 2022: an evidence-based, multidisciplinary approach. J Gastric Cancer. 2023;23:3\u2013106. https:\/\/doi.org\/10.5230\/jgc.2023.23.e11.","journal-title":"J Gastric Cancer"},{"key":"1265_CR4","doi-asserted-by":"publisher","unstructured":"Msika S, Benhamiche AM, Jouve JL, Rat P, Faivre J. Prognostic factors after curative resection for gastric cancer. A population-based study. Eur J Cancer Oxf Engl 1990. 2000;36:390\u20136. https:\/\/doi.org\/10.1016\/s0959-8049(99)00308-1","DOI":"10.1016\/s0959-8049(99)00308-1"},{"key":"1265_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/0002-9610(77)90126-x","volume":"133","author":"B Cady","year":"1977","unstructured":"Cady B, Ramsden DA, Stein A, Haggitt RC. Gastric cancer. Contemporary aspects Am J Surg. 1977;133:423\u20139. https:\/\/doi.org\/10.1016\/0002-9610(77)90126-x.","journal-title":"Contemporary aspects Am J Surg"},{"key":"1265_CR6","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1093\/annonc\/mdt401","volume":"24","author":"N Bernards","year":"2013","unstructured":"Bernards N, Creemers GJ, Nieuwenhuijzen GAP, Bosscha K, Pruijt JFM, Lemmens VEPP. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol Off J Eur Soc Med Oncol. 2013;24:3056\u201360. https:\/\/doi.org\/10.1093\/annonc\/mdt401.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1265_CR7","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1093\/annonc\/mdn026","volume":"19","author":"SH Cheon","year":"2008","unstructured":"Cheon SH, Rha SY, Jeung H-C, Im C-K, Kim SH, Kim HR, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol Off J Eur Soc Med Oncol. 2008;19:1146\u201353. https:\/\/doi.org\/10.1093\/annonc\/mdn026.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1265_CR8","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134:622\u20138. https:\/\/doi.org\/10.1002\/ijc.28373.","journal-title":"Int J Cancer"},{"key":"1265_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215\u201321. https:\/\/doi.org\/10.1016\/S1470-2045(08)70035-4.","journal-title":"Lancet Oncol"},{"key":"1265_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s10120-011-0040-6","volume":"14","author":"T Sano","year":"2011","unstructured":"Sano T, Aiko T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2011;14:97\u2013100. https:\/\/doi.org\/10.1007\/s10120-011-0040-6.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"1265_CR11","doi-asserted-by":"publisher","unstructured":"Tan K-K, Quek TJ-L, Wong N, Li KK, Lim K-H. Emergency surgery for perforated gastric malignancy: an institution\u2019s experience and review of the literature. J Gastrointest Oncol. 2011;2:13\u20138. https:\/\/doi.org\/10.3978\/j.issn.2078-6891.2011.001","DOI":"10.3978\/j.issn.2078-6891.2011.001"},{"key":"1265_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S1470-2045(15)00553-7","volume":"17","author":"K Fujitani","year":"2016","unstructured":"Fujitani K, Yang H-K, Mizusawa J, Kim Y-W, Terashima M, Han S-U, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17:309\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(15)00553-7.","journal-title":"Lancet Oncol"},{"key":"1265_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ags3.12515","volume":"6","author":"K Yoshida","year":"2022","unstructured":"Yoshida K, Yasufuku I, Terashima M, Young Rha S, Moon Bae J, Li G, et al. International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg. 2022;6:227\u201340. https:\/\/doi.org\/10.1002\/ags3.12515.","journal-title":"Ann Gastroenterol Surg"},{"key":"1265_CR14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.4251\/wjgo.v10.i11.398","volume":"10","author":"T Zurleni","year":"2018","unstructured":"Zurleni T, Gjoni E, Altomare M, Rausei S. Conversion surgery for gastric cancer patients: a review. World J Gastrointest Oncol. 2018;10:398\u2013409. https:\/\/doi.org\/10.4251\/wjgo.v10.i11.398.","journal-title":"World J Gastrointest Oncol"},{"key":"1265_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ejso.2020.05.021","volume":"47","author":"M Alyami","year":"2021","unstructured":"Alyami M, Bonnot P-E, Mercier F, Laplace N, Villeneuve L, Passot G, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable peritoneal metastasis from gastric cancer. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2021;47:123\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2020.05.021.","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"key":"1265_CR16","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.3390\/curroncol31030109","volume":"31","author":"M Acs","year":"2024","unstructured":"Acs M, Piso P, Glockzin G. Peritoneal metastatic gastric cancer: local treatment options and recommendations. Curr Oncol. 2024;31:1445\u201359. https:\/\/doi.org\/10.3390\/curroncol31030109.","journal-title":"Curr Oncol"},{"key":"1265_CR17","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1080\/07357907.2018.1551898","volume":"37","author":"R Du","year":"2019","unstructured":"Du R, Hu P, Liu Q, Zhang J. Conversion surgery for unresectable advanced gastric cancer: a systematic review and meta-analysis. Cancer Invest. 2019;37:16\u201328. https:\/\/doi.org\/10.1080\/07357907.2018.1551898.","journal-title":"Cancer Invest"},{"issue":"26","key":"1265_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"2023","author":"Japanese Gastric Cancer Treatment Guidelines","year":"2021","unstructured":"Japanese Gastric Cancer Treatment Guidelines. 6th edition. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2021;2023(26):1\u201325. https:\/\/doi.org\/10.1007\/s10120-022-01331-8.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"1265_CR19","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle\u2013Ottawa scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. 2000."},{"key":"1265_CR20","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8","volume":"17","author":"MK Parmar","year":"1998","unstructured":"Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17:2815\u201334. https:\/\/doi.org\/10.1002\/(sici)1097-0258(19981230)17:24%3c2815::aid-sim110%3e3.0.co;2-8.","journal-title":"Stat Med"},{"key":"1265_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. https:\/\/doi.org\/10.1186\/1745-6215-8-16.","journal-title":"Trials"},{"key":"1265_CR22","doi-asserted-by":"publisher","first-page":"17126","DOI":"10.1002\/cam4.6362","volume":"12","author":"J Fang","year":"2023","unstructured":"Fang J, Huang X, Chen X, Xu Q, Chai T, Huang L, et al. Efficacy of chemotherapy combined with surgical resection for gastric cancer with synchronous ovarian metastasis: a propensity score matching analysis. Cancer Med. 2023;12:17126\u201338. https:\/\/doi.org\/10.1002\/cam4.6362.","journal-title":"Cancer Med"},{"key":"1265_CR23","doi-asserted-by":"publisher","unstructured":"Choe HJ, Kim JW, Han SH, Lee JH, Ahn SH, Park DJ, et al. Conversion surgery in metastatic gastric cancer and cancer dormancy as a prognostic biomarker. Cancers Basel. 2019;12. https:\/\/doi.org\/10.3390\/cancers12010086","DOI":"10.3390\/cancers12010086"},{"key":"1265_CR24","doi-asserted-by":"publisher","first-page":"3504","DOI":"10.1097\/JS9.0000000000001281","volume":"110","author":"P Yu","year":"2024","unstructured":"Yu P, Ding G, Huang X, Wang C, Fang J, Huang L, et al. Genomic and immune microenvironment features influencing chemoimmunotherapy response in gastric cancer with peritoneal metastasis: a retrospective cohort study. Int J Surg. 2024;110:3504\u201317. https:\/\/doi.org\/10.1097\/JS9.0000000000001281.","journal-title":"Int J Surg"},{"key":"1265_CR25","doi-asserted-by":"publisher","first-page":"107314","DOI":"10.1016\/j.ejso.2023.107314","volume":"50","author":"Y Hojo","year":"2024","unstructured":"Hojo Y, Ishida Y, Tomita T, Kurahashi Y, Nakamura T, Kitayama Y, et al. Treatment strategy for successful conversion surgery in clinical stage IVB gastric cancer. Eur J Surg Oncol. 2024;50: 107314. https:\/\/doi.org\/10.1016\/j.ejso.2023.107314.","journal-title":"Eur J Surg Oncol"},{"key":"1265_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s40792-020-00984-w","volume":"6","author":"K Hayano","year":"2020","unstructured":"Hayano K, Watanabe H, Ryuzaki T, Sawada N, Ohira G, Kano M, et al. Prognostic benefit of conversion surgery for HER2 positive stage IV gastric cancer; a case series study of eleven patients treated with trastuzumab-based chemotherapy. Surg Case Rep. 2020;6:219. https:\/\/doi.org\/10.1186\/s40792-020-00984-w.","journal-title":"Surg Case Rep"},{"key":"1265_CR27","doi-asserted-by":"publisher","unstructured":"Nakanishi K, Tanaka C, Kanda M, Miyata K, Furukawa K, Maeda O, et al. Low expectancy of conversion surgery with R0 resection in patients with CEA > 5.0 ng\/mL at the initial RECIST evaluation for metastatic gastric cancer. Cancers Basel. 2023;15. https:\/\/doi.org\/10.3390\/cancers15215197","DOI":"10.3390\/cancers15215197"},{"key":"1265_CR28","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10120-017-0738-1","volume":"21","author":"K Yamaguchi","year":"2018","unstructured":"Yamaguchi K, Yoshida K, Tanahashi T, Takahashi T, Matsuhashi N, Tanaka Y, et al. The long-term survival of stage IV gastric cancer patients with conversion therapy. Gastric Cancer. 2018;21:315\u201323. https:\/\/doi.org\/10.1007\/s10120-017-0738-1.","journal-title":"Gastric Cancer"},{"key":"1265_CR29","doi-asserted-by":"publisher","unstructured":"Nie R, Yuan S, Li Y, Chen S, Li S, Yang L, et al. Risk-stratification model to select conversion surgery for advanced gastric cancer patients. Chin J Cancer Res. 2019;31:178\u201387. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2019.01.13","DOI":"10.21147\/j.issn.1000-9604.2019.01.13"},{"key":"1265_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10120-023-01452-8","volume":"27","author":"Z Yang","year":"2024","unstructured":"Yang Z, Lu S, Shi M, Yuan H, Wang Z, Ni Z, et al. Oncological outcomes of conversion therapy in gastric cancer patients with peritoneal metastasis: a large-scale retrospective cohort study. Gastric Cancer. 2024;27:387\u201399. https:\/\/doi.org\/10.1007\/s10120-023-01452-8.","journal-title":"Gastric Cancer"},{"key":"1265_CR31","doi-asserted-by":"publisher","first-page":"266","DOI":"10.5230\/jgc.2014.14.4.266","volume":"14","author":"SW Kim","year":"2014","unstructured":"Kim SW. The result of conversion surgery in gastric cancer patients with peritoneal seeding. J Gastric Cancer. 2014;14:266\u201370. https:\/\/doi.org\/10.5230\/jgc.2014.14.4.266.","journal-title":"J Gastric Cancer"},{"key":"1265_CR32","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1007\/s00432-021-03516-7","volume":"147","author":"H Ohnuma","year":"2021","unstructured":"Ohnuma H, Sato Y, Onoyama N, Hamaguchi K, Hayasaka N, Sato M, et al. Survival benefit of conversion surgery after intensive chemotherapy for unresectable metastatic gastric cancer: a propensity score-matching analysis. J Cancer Res Clin Oncol. 2021;147:2385\u201396. https:\/\/doi.org\/10.1007\/s00432-021-03516-7.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1265_CR33","doi-asserted-by":"publisher","unstructured":"Canbay E, Canbay Torun B, Cosarcan K, Altunal C, Gurbuz B, Bilgic C, et al. Surgery with hyperthermic intraperitoneal chemotherapy after response to induction chemotherapy in patients with peritoneal metastasis of gastric cancer. J Gastrointest Oncol. 2021;12:S47\u201356. https:\/\/doi.org\/10.21037\/jgo-20-121","DOI":"10.21037\/jgo-20-121"},{"key":"1265_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12957-022-02512-6","volume":"20","author":"A Yago","year":"2022","unstructured":"Yago A, Haruta S, Ueno M, Ogawa Y, Shimoyama H, Ohkura Y, et al. Clinical significance of initial treatment for peritoneal lavage cytology-positive gastric cancer: outcomes according to treatment strategy. World J Surg Oncol. 2022;20:35. https:\/\/doi.org\/10.1186\/s12957-022-02512-6.","journal-title":"World J Surg Oncol"},{"key":"1265_CR35","doi-asserted-by":"publisher","first-page":"4162","DOI":"10.1097\/JS9.0000000000000738","volume":"109","author":"H Liang","year":"2023","unstructured":"Liang H, Yan X, Chen X, Li Z, Qiu Y, Li F, et al. Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage IV gastric cancer. Int J Surg. 2023;109:4162\u201372. https:\/\/doi.org\/10.1097\/JS9.0000000000000738.","journal-title":"Int J Surg"},{"key":"1265_CR36","doi-asserted-by":"publisher","first-page":"5459432","DOI":"10.1155\/2021\/5459432","volume":"2021","author":"TY Lee","year":"2021","unstructured":"Lee TY, Liao GS, Fan HL, Hsieh CB, Chen TW, Chan DC. Conversion surgery for patients with advanced gastric cancer with peritoneal carcinomatosis. J Oncol. 2021;2021:5459432. https:\/\/doi.org\/10.1155\/2021\/5459432.","journal-title":"J Oncol"},{"key":"1265_CR37","doi-asserted-by":"publisher","first-page":"148420","DOI":"10.1155\/2012\/148420","volume":"2012","author":"Y Yonemura","year":"2012","unstructured":"Yonemura Y, Elnemr A, Endou Y, Ishibashi H, Mizumoto A, Miura M, et al. Effects of neoadjuvant intraperitoneal\/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol. 2012;2012: 148420. https:\/\/doi.org\/10.1155\/2012\/148420.","journal-title":"Int J Surg Oncol"},{"key":"1265_CR38","doi-asserted-by":"publisher","first-page":"8597","DOI":"10.1245\/s10434-022-12877-3","volume":"29","author":"DKA Chia","year":"2022","unstructured":"Chia DKA, Sundar R, Kim G, Ang JJ, Lum JHY, Nga ME, et al. Outcomes of a phase II study of intraperitoneal paclitaxel plus systemic capecitabine and oxaliplatin (XELOX) for gastric cancer with peritoneal metastases. Ann Surg Oncol. 2022;29:8597\u2013605. https:\/\/doi.org\/10.1245\/s10434-022-12877-3.","journal-title":"Ann Surg Oncol"},{"key":"1265_CR39","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1245\/s10434-016-5487-6","volume":"24","author":"Y Yonemura","year":"2017","unstructured":"Yonemura Y, Ishibashi H, Hirano M, Mizumoto A, Takeshita K, Noguchi K, et al. Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal\/systemic chemotherapy on peritoneal metastases from gastric cancer. Ann Surg Oncol. 2017;24:478\u201385. https:\/\/doi.org\/10.1245\/s10434-016-5487-6.","journal-title":"Ann Surg Oncol"},{"key":"1265_CR40","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1245\/s10434-009-0706-z","volume":"16","author":"H Okabe","year":"2009","unstructured":"Okabe H, Ueda S, Obama K, Hosogi H, Sakai Y. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol. 2009;16:3227\u201336. https:\/\/doi.org\/10.1245\/s10434-009-0706-z.","journal-title":"Ann Surg Oncol"},{"key":"1265_CR41","doi-asserted-by":"publisher","first-page":"662","DOI":"10.3892\/ol.2011.525","volume":"3","author":"M Yamamoto","year":"2012","unstructured":"Yamamoto M, Matsuyama A, Yoshinaga K, Iwasa T, Tsutsui S, Ishida T. Preliminary trial of surgery after chemotherapy for advanced gastric cancer with peritoneal dissemination. Oncol Lett. 2012;3:662\u20136. https:\/\/doi.org\/10.3892\/ol.2011.525.","journal-title":"Oncol Lett"},{"key":"1265_CR42","first-page":"401","volume":"35","author":"S Ito","year":"2015","unstructured":"Ito S, Oki E, Nakashima Y, Ando K, Hiyoshi Y, Ohgaki K, et al. Clinical significance of adjuvant surgery following chemotherapy for patients with initially unresectable stage IV gastric cancer. Anticancer Res. 2015;35:401\u20136.","journal-title":"Anticancer Res"},{"key":"1265_CR43","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12957-015-0627-1","volume":"13","author":"Z Li","year":"2015","unstructured":"Li Z, Fan B, Shan F, Tang L, Bu Z, Wu A, et al. Gastrectomy in comprehensive treatment of advanced gastric cancer with synchronous liver metastasis: a prospectively comparative study. World J Surg Oncol. 2015;13:212. https:\/\/doi.org\/10.1186\/s12957-015-0627-1.","journal-title":"World J Surg Oncol"},{"key":"1265_CR44","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1007\/s10120-016-0684-3","volume":"20","author":"H Ishigami","year":"2017","unstructured":"Ishigami H, Yamaguchi H, Yamashita H, Asakage M, Kitayama J. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer. 2017;20:128\u201334. https:\/\/doi.org\/10.1007\/s10120-016-0684-3.","journal-title":"Gastric Cancer"},{"key":"1265_CR45","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1245\/s10434-020-09388-4","volume":"28","author":"S Saito","year":"2021","unstructured":"Saito S, Yamaguchi H, Ohzawa H, Miyato H, Kanamaru R, Kurashina K, et al. Intraperitoneal administration of paclitaxel combined with S-1 plus oxaliplatin as induction therapy for patients with advanced gastric cancer with peritoneal metastases. Ann Surg Oncol. 2021;28:3863\u201370. https:\/\/doi.org\/10.1245\/s10434-020-09388-4.","journal-title":"Ann Surg Oncol"},{"key":"1265_CR46","doi-asserted-by":"publisher","first-page":"153303382110363","DOI":"10.1177\/15330338211036310","volume":"20","author":"X Zhang","year":"2021","unstructured":"Zhang X, Huang H, Yang D, Wang P, Huang X, Hu Z, et al. Neoadjuvant intraperitoneal and systemic chemotherapy versus neoadjuvant systemic chemotherapy with docetaxel, oxaliplatin, and S-1 for gastric cancer with peritoneal metastasis: a propensity score matched analysis. Technol Cancer Res Treat. 2021;20:15330338211036310. https:\/\/doi.org\/10.1177\/15330338211036310.","journal-title":"Technol Cancer Res Treat"},{"key":"1265_CR47","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10120-019-00994-0","volume":"23","author":"I Yasufuku","year":"2020","unstructured":"Yasufuku I, Nunobe S, Ida S, Kumagai K, Ohashi M, Hiki N, et al. Conversion therapy for peritoneal lavage cytology-positive type 4 and large type 3 gastric cancer patients selected as candidates for R0 resection by diagnostic staging laparoscopy. Gastric Cancer. 2020;23:319\u201327. https:\/\/doi.org\/10.1007\/s10120-019-00994-0.","journal-title":"Gastric Cancer"},{"key":"1265_CR48","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1007\/s00268-018-4635-5","volume":"42","author":"HS Seo","year":"2018","unstructured":"Seo HS, Song KY, Jung YJ, Park SM, Jeon HM, Kim W, et al. Radical gastrectomy after chemotherapy may prolong survival in stage IV gastric cancer: a Korean multi-institutional analysis. World J Surg. 2018;42:3286\u201393. https:\/\/doi.org\/10.1007\/s00268-018-4635-5.","journal-title":"World J Surg"},{"key":"1265_CR49","first-page":"1485","volume":"26","author":"Z Wu","year":"2021","unstructured":"Wu Z, Fang H. Efficacy of paclitaxel and S-1 combined with apatinib in the conversion therapy for unresectable advanced gastric cancer. J BUON. 2021;26:1485\u201390.","journal-title":"J BUON"},{"key":"1265_CR50","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12876-016-0422-7","volume":"16","author":"Q He","year":"2016","unstructured":"He Q, Ma L, Li Y, Li G. A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis. BMC Gastroenterol. 2016;16:8. https:\/\/doi.org\/10.1186\/s12876-016-0422-7.","journal-title":"BMC Gastroenterol"},{"key":"1265_CR51","doi-asserted-by":"publisher","unstructured":"Shinkai M, Imano M. The clinical effect of conversion surgery for advanced gastric cancer patients with peritoneal metastasis. J Gastrointest Oncol. 2022;13:2169\u201377. https:\/\/doi.org\/10.21037\/jgo-21-431","DOI":"10.21037\/jgo-21-431"},{"key":"1265_CR52","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s10147-023-02384-0","volume":"28","author":"T Nakashima","year":"2023","unstructured":"Nakashima T, Arigami T, Uenosono Y, Matsushita D, Shimonosono M, Tsuruda Y, et al. Clinical significance of intraperitoneal paclitaxel combined with systemic chemotherapy for gastric cancer with peritoneal metastasis. Int J Clin Oncol. 2023;28:1371\u20137. https:\/\/doi.org\/10.1007\/s10147-023-02384-0.","journal-title":"Int J Clin Oncol"},{"key":"1265_CR53","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/ags3.12738","volume":"8","author":"A Morito","year":"2024","unstructured":"Morito A, Eto K, Iwatsuki M, Toihata T, Kosumi K, Iwagami S, et al. Clinical impact of very early recurrence after conversion surgery for stage IV gastric cancer. Ann Gastroenterol Surg. 2024;8:214\u201320. https:\/\/doi.org\/10.1002\/ags3.12738.","journal-title":"Ann Gastroenterol Surg"},{"key":"1265_CR54","doi-asserted-by":"publisher","unstructured":"Ding P, Yang P, Tian Y, Guo H, Liu Y, Zhang Z, et al. Neoadjuvant intraperitoneal and systemic paclitaxel combined with apatinib and S-1 chemotherapy for conversion therapy in gastric cancer patients with positive exfoliative cytology: a prospective study. J Gastrointest Oncol. 2021;12:1416\u201327. https:\/\/doi.org\/10.21037\/jgo-21-375","DOI":"10.21037\/jgo-21-375"},{"key":"1265_CR55","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/BF02306611","volume":"4","author":"T Nakajima","year":"1997","unstructured":"Nakajima T, Ota K, Ishihara S, Oyama S, Nishi M, Ohashi Y, et al. Combined intensive chemotherapy and radical surgery for incurable gastric cancer. Ann Surg Oncol. 1997;4:203\u20138. https:\/\/doi.org\/10.1007\/BF02306611.","journal-title":"Ann Surg Oncol"},{"key":"1265_CR56","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000354420","volume":"85","author":"M Yamamoto","year":"2013","unstructured":"Yamamoto M, Sakaguchi Y, Matsuyama A, Yoshinaga K, Tsutsui S, Ishida T. Surgery after preoperative chemotherapy for patients with unresectable advanced gastric cancer. Oncology. 2013;85:241\u20137. https:\/\/doi.org\/10.1159\/000354420.","journal-title":"Oncology"},{"key":"1265_CR57","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.ejso.2015.04.021","volume":"41","author":"J Kinoshita","year":"2015","unstructured":"Kinoshita J, Fushida S, Tsukada T, Oyama K, Okamoto K, Makino I, et al. Efficacy of conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially resectable stage IV gastric cancer. Eur J Surg Oncol. 2015;41:1354\u201360. https:\/\/doi.org\/10.1016\/j.ejso.2015.04.021.","journal-title":"Eur J Surg Oncol"},{"key":"1265_CR58","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jss.2019.07.044","volume":"245","author":"Y Gong","year":"2020","unstructured":"Gong Y, Wang P, Zhu Z, Zhang J, Huang J, Wang T, et al. Benefits of surgery after neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal metastasis: a meta-analysis. J Surg Res. 2020;245:234\u201343. https:\/\/doi.org\/10.1016\/j.jss.2019.07.044.","journal-title":"J Surg Res"},{"key":"1265_CR59","doi-asserted-by":"publisher","first-page":"10461","DOI":"10.2147\/CMAR.S263320","volume":"12","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Lan X, Li N, Yuan D, Zhang J. Analysis of prognostic factors and design of prognosis model for patients with stage IV gastric cancer following first-line palliative chemotherapy. Cancer Manag Res. 2020;12:10461\u20138. https:\/\/doi.org\/10.2147\/CMAR.S263320.","journal-title":"Cancer Manag Res"},{"key":"1265_CR60","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1093\/jjco\/hyab107","volume":"51","author":"T Hishida","year":"2021","unstructured":"Hishida T, Masai K, Kaseda K, Asakura K, Asamura H. Debulking surgery for malignant tumors: the current status, evidence and future perspectives. Jpn J Clin Oncol. 2021;51:1349\u201362. https:\/\/doi.org\/10.1093\/jjco\/hyab107.","journal-title":"Jpn J Clin Oncol"},{"key":"1265_CR61","doi-asserted-by":"publisher","first-page":"e460","DOI":"10.1634\/theoncologist.2019-0471","volume":"25","author":"M Di Bartolomeo","year":"2020","unstructured":"Di Bartolomeo M, Morano F, Raimondi A, Miceli R, Corallo S, Tamborini E, et al. Prognostic and predictive value of microsatellite instability, inflammatory reaction and PD-L1 in gastric cancer patients treated with either adjuvant 5-FU\/LV or sequential FOLFIRI followed by cisplatin and docetaxel: a translational analysis from the ITACA-S trial. Oncologist. 2020;25:e460\u20138. https:\/\/doi.org\/10.1634\/theoncologist.2019-0471.","journal-title":"Oncologist"},{"key":"1265_CR62","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10120-015-0575-z","volume":"19","author":"K Yoshida","year":"2016","unstructured":"Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2016;19:329\u201338. https:\/\/doi.org\/10.1007\/s10120-015-0575-z.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"1265_CR63","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10120-016-0662-9","volume":"20","author":"D Kobayashi","year":"2017","unstructured":"Kobayashi D, Kodera Y. Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Gastric Cancer. 2017;20:111\u201321. https:\/\/doi.org\/10.1007\/s10120-016-0662-9.","journal-title":"Gastric Cancer"},{"key":"1265_CR64","doi-asserted-by":"publisher","unstructured":"Yonemura Y, Ishibashi H, Mizumoto A, Tukiyama G, Liu Y, Wakama S, et al. The development of peritoneal metastasis from gastric cancer and rationale of treatment according to the mechanism. J Clin Med. 2022;11. https:\/\/doi.org\/10.3390\/jcm11020458","DOI":"10.3390\/jcm11020458"},{"key":"1265_CR65","doi-asserted-by":"publisher","first-page":"7478","DOI":"10.3748\/wjg.v22.i33.7478","volume":"22","author":"J Wei","year":"2016","unstructured":"Wei J, Wu N-D, Liu B-R. Regional but fatal: intraperitoneal metastasis in gastric cancer. World J Gastroenterol. 2016;22:7478. https:\/\/doi.org\/10.3748\/wjg.v22.i33.7478.","journal-title":"World J Gastroenterol"},{"key":"1265_CR66","doi-asserted-by":"publisher","unstructured":"Zhao JJ, Ong C-AJ, Srivastava S, Chia DKA, Ma H, Huang K, et al. Spatially resolved niche and tumor microenvironmental alterations in gastric cancer peritoneal metastases. Gastroenterology. 2024;S0016\u20135085(24)05348\u20134. https:\/\/doi.org\/10.1053\/j.gastro.2024.08.007","DOI":"10.1053\/j.gastro.2024.08.007"},{"key":"1265_CR67","doi-asserted-by":"publisher","unstructured":"Shitara K, Lordick F, Bang Y-J, Enzinger P, Ilson D, Shah MA, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet Lond Engl. 2023;401:1655\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7","DOI":"10.1016\/S0140-6736(23)00620-7"},{"key":"1265_CR68","doi-asserted-by":"publisher","unstructured":"Langellotti L, Fiorillo C, D\u2019Annibale G, Panza E, Pacelli F, Alfieri S, et al. Efficacy of cytoreductive surgery (CRS) + HIPEC in gastric cancer with peritoneal metastasis: systematic review and meta-analysis. Cancers. 2024;16. https:\/\/doi.org\/10.3390\/cancers16101929","DOI":"10.3390\/cancers16101929"},{"key":"1265_CR69","doi-asserted-by":"publisher","unstructured":"Ramalho-Vasconcelos F, Gomes R, Bou\u00e7a-Machado R, Aral M, Nogueiro J, Bou\u00e7a-Machado T, et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of gastric cancer: feasibility, efficacy and safety-a systematic review and meta-analysis. J Clin Med. 2024;13. https:\/\/doi.org\/10.3390\/jcm13113320","DOI":"10.3390\/jcm13113320"},{"key":"1265_CR70","doi-asserted-by":"publisher","first-page":"e225557","DOI":"10.1001\/jamanetworkopen.2022.5557","volume":"5","author":"J-X Lin","year":"2022","unstructured":"Lin J-X, Tang Y-H, Lin G-J, Ma Y-B, Desiderio J, Li P, et al. Association of adjuvant chemotherapy with overall survival among patients with locally advanced gastric cancer after neoadjuvant chemotherapy. JAMA Netw Open. 2022;5: e225557. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.5557.","journal-title":"JAMA Netw Open"},{"key":"1265_CR71","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Y-K Kang","year":"2022","unstructured":"Kang Y-K, Chen L-T, Ryu M-H, Oh D-Y, Oh SC, Chung HC, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23:234\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(21)00692-6.","journal-title":"Lancet Oncol"},{"key":"1265_CR72","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet Lond Engl. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet Lond Engl"},{"key":"1265_CR73","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S1470-2045(20)30169-8","volume":"21","author":"YY Janjigian","year":"2020","unstructured":"Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020;21:821\u201331. https:\/\/doi.org\/10.1016\/S1470-2045(20)30169-8.","journal-title":"Lancet Oncol"},{"key":"1265_CR74","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1200\/JCO.2024.42.3_suppl.281","volume":"42","author":"H Liang","year":"2024","unstructured":"Liang H, Li F, Zhang H, Xie Q, Zhong R, Huang K, et al. Clinical outcomes of conversion surgery following immune checkpoint inhibitors and chemotherapy in stage IV gastric cancer with peritoneal metastasis. J Clin Oncol. 2024;42:281\u2013281. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.281.","journal-title":"J Clin Oncol"},{"key":"1265_CR75","doi-asserted-by":"publisher","unstructured":"Narita Y, Muro K. Updated immunotherapy for gastric cancer. J Clin Med. 2023;12. https:\/\/doi.org\/10.3390\/jcm12072636","DOI":"10.3390\/jcm12072636"},{"key":"1265_CR76","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/jjco\/hyae174","volume":"55","author":"R Kita","year":"2025","unstructured":"Kita R, Yasufuku I, Takahashi N, Mizusawa J, Sano Y, Fukuda H, et al. Randomized controlled phase III study comparing chemotherapy alone versus conversion surgery after a remarkable response to chemotherapy in patients with initially unresectable cStage IVB or pStage IV gastric cancer (JCOG2301, Conversion study). Jpn J Clin Oncol. 2025;55:304\u201310. https:\/\/doi.org\/10.1093\/jjco\/hyae174.","journal-title":"Jpn J Clin Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01265-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01265-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01265-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T16:06:22Z","timestamp":1753200382000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01265-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1265"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01265-1","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"20 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"161"}}